The HSP90 inhibitor analogue 17-AAG (17-allylamino-17-demethoxygeldanamycin) disrupts the HSP90-mutp53 complex, reactivating endogenous MDM2 and CHIP activity, which promotes mutp53 degradation and exerts tumor-suppressive effects (20). Here, MDM2 is linked to neoplasm.